

**DEPARTMENT OF TRANSPORTATION****Federal Aviation Administration****14 CFR Part 39**

[Docket No. FAA-2009-0452; Directorate Identifier 2007-NM-326-AD; Amendment 39-16223; AD 2010-05-13]

RIN 2120-AA64

**Airworthiness Directives; The Boeing Company Model 737-100, -200, -200C, -300, -400, and -500 Series Airplanes**

*Correction*

In rule document 2010-4511 beginning on page 10658 in the issue of Tuesday, March 9, 2010, make the following correction:

On page 10660, in the table, under the heading "Number of U.S.-registered airplanes", the second entry "87" should read "787".

[FR Doc. C1-2010-4511 Filed 3-18-10; 8:45 am]

BILLING CODE 1505-01-D

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration****21 CFR Part 522**

[Docket No. FDA-2010-N-0002]

**Implantation or Injectable Dosage Form New Animal Drugs; Flunixin**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an original abbreviated new animal drug application (ANADA) filed by Cross Vetpharm Group Ltd. The ANADA provides for the use of flunixin meglumine injectable solution in swine.

**DATES:** This rule is effective March 19, 2010.

**FOR FURTHER INFORMATION CONTACT:** John K. Harshman, Center for Veterinary Medicine (HFV-170), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8197, e-mail: [john.harshman@fda.hhs.gov](mailto:john.harshman@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland, filed ANADA 200-489 that provides for use of FLUNAZINE-S (flunixin meglumine) Injectable Solution in swine for control of pyrexia associated with swine respiratory disease. Cross Vetpharm Group Ltd.'s FLUNAZINE-S is

approved as a generic copy of BANAMINE-S, sponsored by Schering-Plough Animal Health Corp. under NADA 101-479. The ANADA is approved as of March 1, 2010, and the regulations are amended in 21 CFR 522.970 to reflect the approval.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33 that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

**List of Subjects in 21 CFR Part 522**

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:

**PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS**

■ 1. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

■ 2. In § 522.970, revise paragraphs (b)(1) and (b)(4) to read as follows:

**§ 522.970 Flunixin.**

\* \* \* \* \*

(b) \* \* \*

(1) See Nos. 000061, 055529, and 061623 for use as in paragraph (e) of this section.

\* \* \* \* \*

(4) See No. 059130 for use as in paragraphs (e)(1) and (e)(2) of this section.

\* \* \* \* \*

Dated: March 12, 2010.

**Bernadette Dunham,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 2010-6038 Filed 3-18-10; 8:45 am]

BILLING CODE 4160-01-S

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration****21 CFR Part 1140**

[Docket No. FDA-1995-N-0259] (formerly Docket No. 1995N-0253)

RIN 0910-AG33

**Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is reissuing a final rule restricting the sale, distribution, and use of cigarettes and smokeless tobacco. As required by the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), FDA is issuing a final rule that is identical to the provisions of the final rule on cigarettes and smokeless tobacco published by FDA in 1996, with certain required exceptions. The rule prohibits the sale of cigarettes and smokeless tobacco to individuals under the age of 18 and imposes specific marketing, labeling, and advertising requirements. Elsewhere in this issue of the **Federal Register**, FDA is issuing an advance notice of proposed rulemaking to obtain information related to the regulation of outdoor advertising of cigarettes and smokeless tobacco.

**DATES:** This rule is effective June 22, 2010.

**FOR FURTHER INFORMATION CONTACT:** Annette Marthaler, Center for Tobacco Products, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850-3229, 877-287-1373, [annette.marthaler@fda.hhs.gov](mailto:annette.marthaler@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:****Table of Contents**

- I. Background
- II. Overview of the Final Rule
- III. Scientific Information That Has Become Available Since the Publication of the 1996 Final Rule
  - A. Access
  - B. Marketing
- IV. Legal Authority
- V. Executive Order 12866